NEW YORK — Backed by an investment from and partnership with Bruker, proteomics firm Adeptrix is ramping up commercialization of its multiplexed MALDI mass spec assays.
Last week, the Beverly, Massachusetts-based company announced it had closed a Series A funding round and planned to use the proceeds to accelerate commercialization of its bead assisted mass spectrometry (BAMS) technology, which combines immuno-enrichment of protein targets with MALDI mass spec to enable rapid, multiplexed analysis of proteins and proteoforms.